Business
Partnership with DAM Health and initial LFT order
Partnership with DAM Health and initial LFT order.
About this update from Cambridge Nutritional Sciences Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8056Q\n Omega Diagnostics Group PLC\n 01 November 2021\n \n \n \n \n OMEGA DIAGNOSTICS GROUP PLC\n \n \n (\"Omega\" or the \"Company\" or the \"Group\")\n \n \n \n \n \n Exclusive Partnership with DAM Health and initial LFT order\n \n \n \n \n \n \n Agreement for Omega's Market Leading, UK Manufactured VISITECT\n \n \n ® COVID-19 Antigen LFT\n \n \n \n \n \n \n Omega (AIM: ODX), the specialist medical diagnostics company focused on industry-leading Global Health (CD4 and COVID-19) and Health and Nutrition products, announces that it has signed a Head of Terms (\"HOT\") partnership agreement with DAM Health Limited (\"DAM Health\"), a leader in fit-to-fly testing and one of the UK's fastest growing and largest in-clinic and mobile test providers for COVID-19. Under the agreement, Omega will exclusively supply its VISITECT® professional use COVID-19 Antigen tests (\"LFT\") to DAM Health's clinics throughout the UK and Europe. Omega has already received an initial purchase order in excess of £750,000 to supply VISITECT® professional use COVID-19 antigen tests to DAM Health.\n \n \n \n \n \n With COVID-19 cases surging again and PCR requirements being replaced with Antigen LFTs, this partnership, which is for an initial period of 12-months, sees two innovative and pioneering UK companies combining their expertise and knowledge as we learn to live with COVID-19. Manufactured in the UK, a recent 2021 study by FIND Diagnostics1, a leading testing authority in Geneva, Switzerland, found the VISITECT® test delivered results of 100% in specificity and 96.4% in sensitivity. Under the agreement, DAM Health agrees to exclusively use, sell and promote Omega's test throughout its network of over 100 clinics in the UK and Europe. DAM Health is currently using approximately 200,000 in-clinic COVID tests per month. \n \n \n \n \n \n Whilst the initial agreement centers around the VISITECT® professional Antigen LFTs, there is the possibility to broaden the partnership to include Omega's VISITECT® antigen self-test LFT (once approved) and for DAM Health to sell Omega's Food Detective product throughout its network. There is also provision to extend this relationship beyond Europe, as DAM Health expand their international network of clinics globally. A further update will be provided ...